ImmunityBio, Inc. IBRX Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s total costs & expenses?
- ImmunityBio, Inc. (IBRX) reported total costs & expenses of $114M in Q1 2026.
- How has ImmunityBio, Inc.'s total costs & expenses changed year-over-year?
- ImmunityBio, Inc.'s total costs & expenses increased by 40.8% year-over-year, from $80.95M to $114M.
- What is the long-term trend for ImmunityBio, Inc.'s total costs & expenses?
- Over 2 years (2023 to 2025), ImmunityBio, Inc.'s total costs & expenses has grown at a 0.9% compound annual growth rate (CAGR), from $362.87M to $369.32M.
- What does total costs & expenses mean?
- Total costs and expenses aggregate all operating and non-operating costs incurred by the company, including research and development, selling, general, and administrative expenses, and cost of revenue. This metric provides a comprehensive view of the company's total cash burn and operational overhead. It is a critical measure for evaluating the company's cost structure and operational discipline.